Raymond James Starts Avalyn Pharma (AVLN) at Outperform

Fri, 02 Oct 2026 05:06:17 -0400

Raymond James analyst Tiago Fauth initiates coverage on Avalyn Pharma (NASDAQ: AVLN) with a Outperform rating and a price target of $60.00.

The analyst comments "We are initiating coverage of Avalyn Pharma (AVLN) at Outperform with a $60 target price. Avalyn is developing inhaled formulations of the two most clinically validated antifibrotics in IPF/ PPF and a potential fixed-dose combo of the two MoAs. At roughly $1B EV for two fully funded Ph2 antifibrotic assets with validated mechanisms of action, we see substantial upside skew into the 2H27 catalysts. "

For an analyst ratings summary and ratings history on Avalyn Pharma

Raymond James Starts Avalyn Pharma (AVLN) at Outperform

Fri, 02 Oct 2026 05:06:17 -0400

Raymond James analyst Tiago Fauth initiates coverage on Avalyn Pharma (NASDAQ: AVLN) with a Outperform rating and a price target of $60.00.

For an analyst ratings summary and ratings history on Avalyn Pharma

Form 4 Avalyn Pharma Inc. For: Sep 15 Filed by: Meyer Robert J.

Thu, 17 Sep 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260917/27075937.html

Form 3 Avalyn Pharma Inc. For: Sep 15 Filed by: Meyer Robert J.

Thu, 17 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260917/27075849.html

Form 8-K Avalyn Pharma Inc. For: Sep 15

Wed, 16 Sep 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260916/27070399.html

Avalyn Pharma adds ex-FDA official Robert Meyer to its board

Wed, 16 Sep 2026 16:01:23 -0400

Avalyn Pharma Inc. (Nasdaq: AVLN) announced the appointment of Robert J. Meyer, MD, to its board of directors, according to a company statement.

Dr. Meyer most recently served as Principal of Drug and Biologics Products at Greenleaf Health, now Eliquent Life Sciences, an FDA regulatory consulting firm. He previously served as Director of the Virginia Center for Translational and Regulatory Sciences at the University of Virginia School of Medicine.

Dr. Meyer spent more than 15 years at the FDA, where he held roles including Director of the Office of Drug Evaluation II within the Center for Drug Evaluation and Research, overseeing review

Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors

Wed, 16 Sep 2026 16:01:00 -0400

BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN) (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced the appointment of Robert (Bob) J. Meyer, MD, a distinguished pulmonary physician and former senior U.S. Food and Drug Administration (“FDA”) leader, to its Board of Directors (the “Board”). Dr. Meyer most recently served as Principal of Drug and Biologics Products at Greenleaf Health, now Eliquent Life Sciences.

"On behalf of the entire Avalyn team, I am thrilled to welcome Bob to

Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors

Wed, 16 Sep 2026 16:01:00 -0400

"On behalf of the entire Avalyn team, I am thrilled to welcome Bob to

Avalyn Pharma presents AP01 lung distribution data at ERS 2026

Tue, 08 Sep 2026 08:04:17 -0400

Avalyn Pharma Inc. (Nasdaq: AVLN) presented two data sets at the European Respiratory Society International Congress 2026 in Barcelona, Spain, on Sept. 8, 2026, covering predicted aerosol distribution of its inhaled therapy AP01 and patient survey findings related to clinical trial participation in idiopathic pulmonary fibrosis (IPF).

Using the Ebenbuild Twinhale in silico modeling platform, Avalyn simulated AP01 aerosol deposition across three-dimensional lung models derived from high-resolution computed tomography scans of healthy, mild IPF, and severe IPF lungs. The modeling predicted broad distribution of AP01 throughout the lung in all three models, with alveolar and thoracic tissues accounting for the majority

Avalyn Pharma presents AP01 lung distribution data at ERS 2026

Tue, 08 Sep 2026 08:04:17 -0400

Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis

Tue, 08 Sep 2026 08:00:00 -0400

In silico modeling predicts robust AP01 distribution in healthy and fibrotic lungs, even in severe disease

Patient survey findings suggest that clear communication, transparent discussions of potential benefits and risks, and efforts to reduce logistical burden may support engagement in future pulmonary fibrosis clinical studies

BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced new data demonstrating predicted aerosol distribution of AP01 and survey data highlighting patient perspectives on participation in clinical

Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis

Tue, 08 Sep 2026 08:00:00 -0400

In silico modeling predicts robust AP01 distribution in healthy and fibrotic lungs, even in severe disease

Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Tue, 08 Sep 2026 08:00:00 -0400

BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced Avalyn management will participate in a fireside chat at the Morgan Stanley 24^th Annual Global Healthcare Conference in New York City on September 14, 2026, at 1:50-2:25 p.m. ET.

Access to the live webcast of this event, and the archived recording, will be posted under the News & Events page of the Investor section of the company’s website at https://investors.avalynpharma.com/.

About Avalyn

Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Tue, 08 Sep 2026 08:00:00 -0400

BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced Avalyn management will participate in a fireside chat at the Morgan Stanley 24^th Annual Global Healthcare Conference in New York City on September 14, 2026, at 1:50-2:25 p.m. ET.

Access to the live webcast of this event, and the archived recording, will be posted under the News & Events page of the Investor section of the company’s website at https://investors.avalynpharma.com/.

About Avalyn

Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026

Mon, 24 Aug 2026 16:01:00 -0400

Presentations describe integration of patient perspective into clinical trial design and data modeling AP01 distribution in the lungs
BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced two upcoming poster presentations at the European Respiratory Society (ERS) International Congress 2026, being held September 5-9, 2026, in Barcelona, Spain.

ERS 2026 Poster Presentation Details:

Poster Title: Understanding patient perspectives on IPF clinical trial participation: Preferences, motivations, and comfort with study design
Poster Session: #246: Real-world studies:

Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026

Mon, 24 Aug 2026 16:01:00 -0400

Presentations describe integration of patient perspective into clinical trial design and data modeling AP01 distribution in the lungs
BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced two upcoming poster presentations at the European Respiratory Society (ERS) International Congress 2026, being held September 5-9, 2026, in Barcelona, Spain.

ERS 2026 Poster Presentation Details:

Poster Title: Understanding patient perspectives on IPF clinical trial participation: Preferences, motivations, and comfort with study design
Poster Session: #246: Real-world studies:

Form SCHEDULE 13G Avalyn Pharma Inc. Filed by: Novo Holdings A/S

Fri, 14 Aug 2026 17:05:00 -0400
si-local-file:///var/storage/secattach/20260814/26932552.html

Form SCHEDULE 13G Avalyn Pharma Inc. Filed by: Novo Holdings A/S

Fri, 14 Aug 2026 17:05:00 -0400
si-local-file:///var/storage/secattach/20260814/26932552.html

Avalyn Pharma (AVLN) PT Raised to $57 at Morgan Stanley

Thu, 13 Aug 2026 08:08:26 -0400
Morgan Stanley analyst Judah Frommer raised the price target on Avalyn Pharma (NASDAQ: AVLN) to $57.00 (from $53.00) while maintaining a Overweight rating.

Form 10-Q Avalyn Pharma Inc. For: Jun 30

Wed, 12 Aug 2026 08:15:00 -0400
si-local-file:///var/storage/secattach/20260812/26909345.html

Form 10-Q Avalyn Pharma Inc. For: Jun 30

Wed, 12 Aug 2026 08:15:00 -0400
si-local-file:///var/storage/secattach/20260812/26909345.html

Form 8-K Avalyn Pharma Inc. For: Aug 12

Wed, 12 Aug 2026 08:07:00 -0400
si-local-file:///var/storage/secattach/20260812/26909289.html

Form 8-K Avalyn Pharma Inc. For: Aug 12

Wed, 12 Aug 2026 08:07:00 -0400
si-local-file:///var/storage/secattach/20260812/26909289.html

Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Wed, 12 Aug 2026 08:00:00 -0400

Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected in the second half of 2027

Two abstracts accepted for presentation at the European Respiratory Society (ERS) Congress, including data modeling AP01 lung tissue distribution

Ended the second quarter of 2026 with $413.5 million in cash, cash equivalents and marketable securities; cash runway projected into 2029

BOSTON, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today

Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Wed, 12 Aug 2026 08:00:00 -0400

Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected in the second half of 2027

Two abstracts accepted for presentation at the European Respiratory Society (ERS) Congress, including data modeling AP01 lung tissue distribution

Ended the second quarter of 2026 with $413.5 million in cash, cash equivalents and marketable securities; cash runway projected into 2029

BOSTON, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today

StreetInsider.com News Articles

Raymond James Starts Avalyn Pharma (AVLN) at Outperform

Raymond James Starts Avalyn Pharma (AVLN) at Outperform

Form 4 Avalyn Pharma Inc. For: Sep 15 Filed by: Meyer Robert J.

Form 3 Avalyn Pharma Inc. For: Sep 15 Filed by: Meyer Robert J.

Form 8-K Avalyn Pharma Inc. For: Sep 15

Avalyn Pharma adds ex-FDA official Robert Meyer to its board

Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors

Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors

Avalyn Pharma presents AP01 lung distribution data at ERS 2026

Avalyn Pharma presents AP01 lung distribution data at ERS 2026

Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis

Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis

Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026

Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026

Form SCHEDULE 13G Avalyn Pharma Inc. Filed by: Novo Holdings A/S

Form SCHEDULE 13G Avalyn Pharma Inc. Filed by: Novo Holdings A/S

Avalyn Pharma (AVLN) PT Raised to $57 at Morgan Stanley

Form 10-Q Avalyn Pharma Inc. For: Jun 30

Form 10-Q Avalyn Pharma Inc. For: Jun 30

Form 8-K Avalyn Pharma Inc. For: Aug 12

Form 8-K Avalyn Pharma Inc. For: Aug 12

Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights